Long GV, Schachter J, Ribas A, et al. 4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006. ASCO 2018. J Clin Oncol. 2018;36 (suppl; abstr 9503).
ECCO 2017: Grote verschillen in Nederland bij opvolgen behandelrichtlijnen kanker
jan 2017 | Borstkanker, Longoncologie, Maag-darm-leveroncologie, Uro-oncologie